Xiaobo Du

2.5k total citations · 1 hit paper
90 papers, 1.5k citations indexed

About

Xiaobo Du is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Xiaobo Du has authored 90 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 21 papers in Surgery. Recurrent topics in Xiaobo Du's work include Advanced Radiotherapy Techniques (11 papers), Esophageal Cancer Research and Treatment (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Xiaobo Du is often cited by papers focused on Advanced Radiotherapy Techniques (11 papers), Esophageal Cancer Research and Treatment (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Xiaobo Du collaborates with scholars based in China, United States and South Korea. Xiaobo Du's co-authors include Binwei Lin, Gang Feng, Tangzhi Dai, Hong Xia, Juan Wang, Qi‐Dai Chen, Yan He, Yong‐Lai Zhang, Hong‐Bo Sun and Ye Tian and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Xiaobo Du

75 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FLASH Radiotherapy: History and Future

2021 123 citations Binwei Lin, Feng Gao et al. Frontiers in Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaobo Du China	17	419	339	325	250	160	90	1.5k
Gwo Fuang Ho Malaysia	24	291 0.7×	381 1.1×	789 2.4×	90 0.4×	162 1.0×	107	1.7k
Yolanda D. Tseng United States	20	612 1.5×	314 0.9×	451 1.4×	112 0.4×	347 2.2×	96	2.0k
Mei Li China	24	642 1.5×	97 0.3×	187 0.6×	166 0.7×	122 0.8×	82	1.8k
Rakesh Patel United States	30	239 0.6×	309 0.9×	178 0.5×	188 0.8×	371 2.3×	129	2.7k
Chen-Hsi Hsieh Taiwan	22	297 0.7×	360 1.1×	281 0.9×	82 0.3×	290 1.8×	112	1.6k
Lin Zhou China	34	973 2.3×	959 2.8×	948 2.9×	178 0.7×	589 3.7×	261	4.5k
Kheng‐Wei Yeoh Singapore	3	686 1.6×	612 1.8×	469 1.4×	481 1.9×	122 0.8×	5	2.4k
Tatiana V. Esipova United States	20	820 2.0×	354 1.0×	88 0.3×	385 1.5×	111 0.7×	28	2.0k
Mousumi Banerjee India	24	426 1.0×	620 1.8×	318 1.0×	50 0.2×	269 1.7×	74	1.8k

Countries citing papers authored by Xiaobo Du

Since Specialization

Citations

This map shows the geographic impact of Xiaobo Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobo Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobo Du more than expected).

Fields of papers citing papers by Xiaobo Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobo Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobo Du. The network helps show where Xiaobo Du may publish in the future.

Co-authorship network of co-authors of Xiaobo Du

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobo Du. A scholar is included among the top collaborators of Xiaobo Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobo Du. Xiaobo Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Dan, Chunyan Wu, Liming Xiao, et al.. (2025). Diffuse myocardial infiltration in secondary cardiac lymphoma: A case report. Oncology Letters. 29(6). 1–6.

Wang, Decai, Xiyue Yang, Binwei Lin, et al.. (2025). High‑intensity focused ultrasound thermal ablation boosts the efficacy of immune checkpoint inhibitors in advanced cancers with liver metastases: A single‑center retrospective cohort study. Oncology Letters. 29(3). 124–124.

Ding, Ran, Runda Guo, Hu Zhang, et al.. (2025). Unveiling the Interfacial Properties of Organic Single‐Crystal Hole‐Transporting Layers for High‐Performance Light‐Emitting Devices. SmartMat. 6(1). 8 indexed citations

Xu, Haonan, et al.. (2025). Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer. BMC Cancer. 25(1). 985–985.

Zhang, Li, Wenfeng Fang, Yu Zhao, et al.. (2025). 1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR ⁺ NSCLC progressed on EGFR-TKI treatment. A1592–A1592.

Lin, Binwei, Huan Du, Haonan Xu, et al.. (2025). The influence of beam parameters on FLASH effect. Frontiers in Oncology. 15. 1431700–1431700.

Xu, Haonan, et al.. (2024). Combination of radiotherapy and flap reconstruction for cancer treatments (Review). Molecular and Clinical Oncology. 20(5). 34–34. 4 indexed citations

Liu, Bin, Xingxiang Pu, Lin Wu, et al.. (2024). A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 2534–2534. 1 indexed citations

Zhang, Li, Wen‐Feng Fang, Yuanyuan Zhao, et al.. (2024). Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 8508–8508. 8 indexed citations

10.

Qi, Ke, Qiang Yang, Minjie Zhou, et al.. (2024). A Dual-Modal, Label-Free Raman Imaging Method for Rapid Virtual Staining of Large-Area Breast Cancer Tissue Sections. Analytical Chemistry. 96(33). 13410–13420. 1 indexed citations

11.

Xu, Haonan, et al.. (2024). Efficacy and safety of anlotinib combined with S‑1 as a third‑ or later‑line treatment for advanced non‑small cell lung cancer in China: A systematic review and meta‑analysis. Oncology Letters. 28(6). 613–613.

12.

Gao, Feng, Binwei Lin, Yiwei Yang, et al.. (2024). Effects of ultra-high dose rate radiotherapy with different fractions and dose rate on acute and chronic lung injury in mice. Heliyon. 10(22). e40298–e40298. 2 indexed citations

13.

Lin, Binwei, Dan Huang, Huan Du, et al.. (2021). Whole-Brain Radiation Therapy With Simultaneous Integrated Boost Versus Whole-Brain Radiation Therapy Plus Stereotactic Radiosurgery for the Treatment of Brain Metastasis From Lung Cancer. Frontiers in Oncology. 11. 631422–631422. 19 indexed citations

14.

Yang, Beibei, Dandan Wang, Geng Li, et al.. (2020). Effect of tumor necrosis factor superfamily on inflammatory bowel disease. 4(1). 55–58.

15.

Li, Jie, Zhongzheng Xiang, Huan Du, et al.. (2020). Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiotherapy and Oncology. 154. 201–206. 27 indexed citations

16.

Yang, Xiyue, et al.. (2019). Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial. Asian Pacific Journal of Cancer Prevention. 20(12). 3849–3853. 5 indexed citations

17.

Wu, Rong, He Hu, Zhenhua Zhao, et al.. (2018). Clinical application of oral meglumine diatrizoate esophagogram in screening esophageal fistula during radiotherapy for esophageal cancer. Medicine. 97(18). e0668–e0668. 4 indexed citations

18.

Wu, Rong, Jiafu Feng, Yuwei Yang, et al.. (2017). Significance of Serum Total Oxidant/Antioxidant Status in Patients with Colorectal Cancer. PLoS ONE. 12(1). e0170003–e0170003. 92 indexed citations

19.

Li, Jie & Xiaobo Du. (2016). Progress in research on the relationships among tumor blood supply patterns. Oncology and Translational Medicine. 2(3). 138–141. 1 indexed citations

20.

Tan, Benxu, W. Yao, Jun Ge, et al.. (2011). Prognostic influence of metformin as first‐line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer. 117(22). 5103–5111. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact